Onkológia 1/2013
Gastrointestinal toxicity, hepatotoxicity and nephrotoxicity of targeted treatment
We have witnessed marked advancement in the treatment of malignant diseases. Progress in surgical techniques, new technologies in radiation oncology and incorporation of targeted treatment in the last decade undoubtedly improved prognosis of our patients with malignancies. Targeted agents often have their own, intrinsic toxicities, different from cytotoxic chemotherapy. We have summarized common or clinically significant side effects of available targeted agents on the gastrointestinal system, liver and kidneys. Several preventative follow-up schedules for these patients are noted.
Keywords: tyrosine-kinase inhibitors, mTOR inhibitors, monoclonal antibodies, hepatotoxicity, nephrotoxicity, gastrointestinal toxicity.
